← NewsAll
Artificial intelligence may renew mental health prescriptions in Utah
Summary
Legion Health will pilot an AI system next month in Utah that can renew certain lower-risk psychiatric maintenance medications after patient consent; the rollout starts with staged doctor oversight and requires a $20 monthly subscription.
Content
Legion Health will begin a pilot next month in Utah that allows an AI to renew certain psychiatric maintenance medications that a human doctor previously prescribed. The program is limited to lower-risk drugs and requires patients to opt in, verify identity, and pay a monthly subscription. The AI conducts a brief safety review and is paired with human clinicians during early stages. Utah’s regulatory approach and wide shortages in medical providers are cited as reasons for testing the system there.
Key details:
- The AI renewal feature is limited to medications Legion classifies as lower-risk, including SSRIs, bupropion (Wellbutrin), trazodone, and mirtazapine.
- Patients are informed they are interacting with an AI, must give consent, and undergo identity verification before the system performs a two-minute focused safety review covering interactions, side effects, and psychiatric warning signs.
- Any red flag identified by the AI triggers immediate human clinician takeover, and patients can request a human review at any time.
- The pilot uses a phased rollout: the first 250 prescriptions will have direct doctor oversight, the next 1,000 will receive post-evaluation reviews by doctors, and only after those stages will the AI operate without routine immediate oversight.
- Utah officials have created regulatory sandboxes to allow controlled testing of AI technologies, and the state has designated all 29 counties as health professional shortage areas.
Summary:
The pilot intends to shorten waits and reduce travel and cost burdens for some patients while maintaining clinician involvement in early stages. The company says it plans to expand to other states after the phased evaluation, and Utah’s regulatory framework enabled the initial test.
